MK-777

• Dry fill capsules, 10 mg, 60 count, 600 mg total
• 30 mL liquid solution, 20 mg per mL, 600 mg total
• 1 g powder

Research indicates MK-777 may

• Activate the ghrelin receptor (GHSR1a) to stimulate growth hormone release
• Increase pulsatile GH secretion rather than delivering exogenous GH
• Elevate circulating IGF-1 as a downstream response to GH signaling
• Increase appetite signaling via ghrelin pathway activation
• Influence sleep related endpoints, especially slow wave sleep metrics in some models
• Shift substrate utilization and water balance endpoints through GH and IGF-1 related physiology

MK-777 is commonly studied for potential roles in

• Growth hormone axis signaling (GH and IGF-1)
• Age related catabolic states and lean mass preservation models
• Sleep architecture research (sleep depth and continuity endpoints)
• Recovery capacity and training stress models (performance and adaptation endpoints)
• Bone metabolism and connective tissue related endpoints in preclinical settings
• Appetite regulation and energy intake models

Potentially observed or monitored effects in research settings include: Because metabolic markers can shift, careful monitoring is typically emphasized in study design.

• Increased appetite, sometimes pronounced
• Water retention and edema like signals in some subjects
• Lethargy or daytime sleepiness in some cases, especially early exposure
• Headache or gastrointestinal discomfort
• Elevated fasting glucose or reduced insulin sensitivity markers in some individuals
• Increased blood pressure signals in susceptible subjects, often secondary to fluid retention or appetite driven intake